Trial Profile
Phase I/II Study With Temsirolimus Versus no add-on in Patients With Castration Resistant Prostate Cancer (CRPC) Receiving First-line Docetaxel Chemotherapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CEPTAS
- 26 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Feb 2015 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 03 Feb 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.